中国药物警戒 ›› 2022, Vol. 19 ›› Issue (5): 469-474.
DOI: 10.19803/j.1672-8629.2022.05.01
张晓朦1,2, 吕锦涛1,2, 张冰1,2,*, 林志健1,2, 刘荣雪1
收稿日期:
2022-02-08
出版日期:
2022-05-15
发布日期:
2022-05-18
通讯作者:
*张冰,女,博士,教授·博导,主任医师,中药药物警戒与合理用药、中药药性理论与名老中医传承、中药防治代谢性疾病。E-mail:zhangbing6@263.net
作者简介:
张晓朦,女,博士,讲师,中药药物警戒与合理用药。
基金资助:
ZHANG Xiaomeng1,2, LYU Jintao1,2, ZHANG Bing1,2,*, LIN Zhijian1,2, LIU Rongxue1
Received:
2022-02-08
Online:
2022-05-15
Published:
2022-05-18
摘要: 目的 探索蟾酥类注射液治疗肝癌的风险评价与预警模式,为临床提供示范研究。 方法 检索中国知网、万方数据、SinoMed、PubMed等期刊文献数据库,检索时间为建库至2022年1月31日,收集蟾酥类注射液(华蟾素注射液、得力生注射液、蟾酥注射液),治疗肝癌的随机对照试验,采用多准则决策模型评价其在不同应用条件下的效益-风险(BRA),基于评价结果采用熵权可拓物元模型预测该类药物应用的风险响应等级。 结果 共纳入64项蟾酥类注射液治疗肝癌的随机对照试验,评价结果显示,未联用经动脉化疗栓塞术治疗手段的组别BRA值81.55%高于联用者;应用华蟾素注射液的组别BRA值100%高于蟾酥注射液、得力生注射液;常规剂量组优于超说明书用量组;28 d内短疗程组BRA值优于长疗程19[95%CI(9.42,28.88)]。疗程因素需作为一级预警响应,临床给予特别关注。 结论 多准则决策联合熵权可拓物元模型可作为中药风险评价与预警的研究基础,为临床开展中药药物警戒提供依据。
中图分类号:
张晓朦, 吕锦涛, 张冰, 林志健, 刘荣雪. 蟾酥类注射液治疗肝癌的风险评价与预警研究[J]. 中国药物警戒, 2022, 19(5): 469-474.
ZHANG Xiaomeng, LYU Jintao, ZHANG Bing, LIN Zhijian, LIU Rongxue. Risk assessment and pre-warning of injection within Bufonis Venenum in the treatment of liver cancer[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 469-474.
[1] YING JQ, YANG M, ZHANG PZ, et al.Processing evolution, chemical components and pharmacological effects of Bufonis Venenum[J].China Journal of Chinese Materia Medica(中国中药杂志), 2021, 46(14): 3529-3539. [2] YU CY, MENG LJ, JIANG N, et al.Research progress on chemical constituents and pharmacological activities of Bofonis Corium[J].Chinese Traditional and Herbal Drugs(中草药), 2021, 52(4): 1206-1220. [3] LASSANDRO G, PICCHI SG, BIANCO A, et al.Effectiveness and safety in radiofrequency ablation of pulmonary metastases from HCC: a five years study[J]. Med Oncol, 2020, 37(4): 25. [4] ZHU DC, XIAO W.Research progress on the anti-tumor effect of toad venom and its mechanism[J]. Lishizhen Medicine and Materia Medica Research(时珍国医国药), 2017, 28(6): 1441-1444. [5] FANG MD, WANG MY.Research progress on anticancer effects of several poisonous animal medicinal materials and their active ingredients[J]. Jiangsu Journal of Traditional Chinese Medicine(江苏中医药), 2007(11): 92-93. [6] SUN DX, WANG CX.Short-term efficacy of huachansu injection combined with TACE and microwave ablation in the treatment of advanced hepatocellular carcinoma with HBV infection[J]. Systems Medicine(系统医学), 2019, 4(22): 133-135. [7] GAN SM.Observation of curative effect of cinobufacini injection combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer[J]. World Latest Medicine Information(世界最新医学信息文摘), 2019, 19(78): 172-173. [8] LI J, ZENG BZ, SUN ZG.Clinical study on arterial catheter infusion cinobufotain combined with transcatheter arterial Chemoembolization in treatment of primary liver cancer[J]. Hubei Journal of Traditional Chinese Medicine(湖北中医杂志), 2019, 41(1): 12-15. [9] LI SY, WU S, CHEN TS.Effect of portal venous perfusion cinobufacini injection combined with TACE in patients with intermediate hepatocellular carcinoma[J]. Clinical Journal of Medical Officers(临床军医杂志), 2017, 45(9): 884-886. [10] CHEN KR, ZHANG HW, MA JL.Clinical efficacy of TACE combined with cinobufacini injection and entecavir dispersible tablets in hepatocellular carcinoma[J]. Electronic Journal of Clinical Medical Literature(临床医药文献电子杂志), 2017, 4(56): 11021-11022. [11] LI J, ZENG BZ, ZHAO N.60 cases of advanced pimary liver cancer treated by arterial catheter perfusion with cinobufasu injection[J].Journal of North Pharmacy(北方药学), 2017, 14(4): 79. [12] JIA JY.Clinical effect of cinobufagin combined with transhepatic arterial chemotherapy and embolization in the treatment of primary hepatocellu-lar carcinoma[J]. China Modern Medicine(中国当代医药), 2016, 23(8): 52-54,57. [13] SHEN JJ, TAN SZ.Transcatheter arterial embolization with cinobufacini on terminal stage of hepatocellular carcinoma[J]. Jilin Journal of Chinese Medicine(吉林中医药), 2015, 35(7): 678-680. [14] DENG ZY, DUAN HB.Clinical observation of cinobufacini combined with TACE in the treatment of primary liver cancer[J]. Tianjin Journal of Traditional Chinese Medicine(天津中医药), 2015, 32(5): 275-278. [15] CHEN SZ, ZHANG MZ, ZHANG YX.Interventional treatment of primary liver cancer with recombinant human endostatin combined with cinobufacini[J]. Practical Journal of Medicine & Pharmacy(实用医药杂志), 2014, 31(8): 702-704. [16] YANG GH, XUE T, LI P.Study of cinobufacini injection intervention on serum prealbumin and vascular endothelial growth factor in patients with primary liver cancer[J]. Chinese Archives of Traditional Chinese Medicine(中华中医药学刊), 2014, 32(5): 1086-1088. [17] WEI YL, HUANG ZT, ZENG F.Clinical analysis of cinobufacini combined with interventional therapy in the treatment of 110 patients with advanced liver cancer[J]. Journal of Minimally Invasive Medicine(微创医学), 2013, 8(6): 744-745. [18] DONG ME.Observation of curative effect of cinobufacin injection combined with low-dose chemotherapy in the treatment of advanced liver cancer[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine(现代中西医结合杂志), 2013, 22(36): 4050-4051. [19] MAO WD.Clinical study on the intervention of cinobufacini injection on postoperative recurrence of primary liver cancer[J].Anhui Medical and Pharmaceutical Journal(安徽医药),2013,17(12):2144-2145. [20] SU Y, YANG JQ, GUO CQ.Cinobufasu injection combined with transcatheter hepatic arterial chemoembolization in the treatment of advanced primary liver cancer[J]. Journal of Basic and Clinical Oncology(肿瘤基础与临床), 2013, 26(3): 245-246. [21] QU XR, WANG QS, WANG SX, et al.Observation on the short-term curative effect of Kangai, Shenqi Fuzheng, Chansu injection combined with interventional therapy in the treatment of primary middle-advanced liver cancer[J]. Hebei Medical Journal(河北医药), 2013, 35(11): 1728-1729. [22] YU JG.Clinical observation of cinobufacin injection combined with hepatic arterial chemoembolization in the treatment of primary liver cancer[J]. Modern Digestion & Intervention(现代消化及介入诊疗), 2013, 18(1): 32-33. [23] SONG GP.Effect of cinobufagin injection on prevention of recurrence of primary liver cancer with radical resection[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2012, 18(22): 307-309. [24] HE SL, LIU LM, SUN XJ, et al.Effect of huachansu injection sequence TACE including oxaliplatin regimen for advanced hepatocelluler carcinoma[J]. Chinese Journal of Clinicians(Electronic Edition)[中华临床医师杂志(电子版)], 2012, 6(14): 3880-3883. [25] QU JR, WANG QS, DAI J, et al.Prevention and treatment effect of Chansu injection on adverse reactions after interventional intervention for primary liver cancer[J]. Chinese Journal of Difficult and Complicated Cases(疑难病杂志), 2012, 11(4): 294-295. [26] ZHANG HB, LI XF, MA ZQ.Observation on the curative effect of intravenous infusion of cinobufacini injection combined with interventional therapy for liver cancer[J]. Chinese Journal of Modern Drug Application(中国现代药物应用), 2012, 6(6): 77-78. [27] QIAO CX, LIU Q, LING CQ.Clinical analysis of 10 cases of primary liver cancer treated by Cinobufasu injection via hepatic artery[J]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases(中西医结合肝病杂志), 2011, 21(6): 369-371. [28] KE J, LU K, LI Y.Clinical observation of patients with primary liver cancer treated by Cinobufagin Injection combined with transcatheter arterial chemoembolization (TACE)[J]. China Practical Medicine(中国实用医药), 2011, 6(34): 1-2. [29] KOU CY, XU Z.Clinical analysis of cinobufacini combined with TACE in the treatment of advanced liver cancer[J]. Chinese Journal of Misdiagnostics(中国误诊学杂志), 2011, 11(25): 6151-6152. [30] ZHANG TS, SHAN GZ.Continuous transarterial infusion with cinobufotain combined with transhepatic arterial embolism in the treatment of 32 cases with primary hepatocellular carcinoma[J].Journal of Chinese Oncology(肿瘤学杂志), 2011, 17(7): 557-558. [31] YUAN CY, XIE Q, ZENG BR, et al.Clinical observation of 20 cases of primary liver cancer treated by continuous hepatic arterial perfusion of cinobufacini combined with vascular embolization[J].Guiding Journal of Traditional Chinese Medicine and Pharmacy(中医药导报), 2011, 17(2): 16-18. [32] FU ZL, QU ZH, WANG Y.Clinical study of cinobufacini combined with interventional therapy in the treatment of advanced liver cancer[J]. China Practical Medicine(中国实用医药), 2010, 5(34): 107-108. [33] LIU YQ, YU ZH, SHAO ZH, et al.Clinical observation of intravenous injection of cinobufacini combined with TACE in the treatment of liver cancer[J]. Chinese Rural Health Service Administration(中国农村卫生事业管理), 2010, 30(5): 402-404. [34] XUE Q, LU LQ, YUAN GR, et al.Clinical study on 32 cases of middle and advanced liver cancer patients treated with cinobufulin combined with TACE[J]. Jiangsu Journal of Traditional Chinese Medicine(江苏中医药), 2010, 42(2): 22-24. [35] LIU XH, FU H, ZHU QH, et al.Clinical study of cinobufacini injection combined with TACE in the treatment of liver cancer[J].Chinese Journal of Modern Drug Application(中国现代药物应用), 2009, 3(23): 134-135. [36] SHEN JJ.The clinical effect of Cinobufagin injection by transcatheter arterial chemoembolization (TACE) combined with intravenous on treating primary liver cancer (PLC)[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2009, 25(3): 207-209. [37] LI Q, SUN BM, PENG YH, et al.Clinical Study on the Treatment of Primary Liver Cancer by Cinobufotain Combined with Transcatheter Arterial Chemoembolization[J]. Academic Journal of Shanghai University of Traditional Chinese Medicine(上海中医药大学学报), 2008(2): 32-34. [38] WANG H, YANG G.Clinical efficacy of Delisheng injection combined with hepatic artery intervention in the treatment of primary liver cancer[J]. Journal of Modern Oncology(现代肿瘤医学), 2007(11): 1648-1649. [39] YOU SY, FAN H, HUAN ZG, et al.Clinical study on the treatment of intermediate and advanced stage liver cancer with combination of arterial perfusion of cinobufotalin and embolotherapy[J]. Hebei Medicine(河北医学), 2006(11): 1096-1100. [40] XIANG DB, XIE JY, WANG D, et al.Clinical study of Delisheng injection combined with transcatheter arterial chemoembolization in treatment of primary hepatocellular carcinoma[J]. Journal of Modern Oncology(现代肿瘤医学), 2006(7): 861-862. [41] LI WH, YIN JP, WANG XH, et al.Observation of the curative effect of combined embolization and chemotherapy with cinobufacini in advanced hepatocellular carcinoma[J]. World Clinical Drugs(世界临床药物), 2006(5): 310-312. [42] ZHOU JS, LU H, WU XD, et al.Effects of huachan-shu injection combind with transcatheter arterial chemoembolization on patients with advanced unresectable hepatocelluler carcinoma[J]. Chinese Journal of Primary Medicine and Pharmacy(中国基层医药), 2006(4): 571-572. [43] YANG YG, LI J, MA YH, et al.Observation of curative effect of cinobufacini combined with interventional chemotherapy in the treatment of advanced liver cancer[J]. Journal of Practical Traditional Chinese Medicine(实用中医药杂志), 2006(1): 20. [44] YU QT, MENG ZB.Clinical study of cinobufacini combined with hepatic artery intubation in the treatment of advanced hepatocellular carcinoma[J]. Journal of Guangxi University of Chinese Medicine(广西中医学院学报), 2004(3): 35-37. [45] SUN ZJ, PAN CE, WANG GJ.Clinical observation on cinobufotain in treating hepatocellular carcinoma after transcather arterial chemoembolization[J]. Cancer Research on Prevention and Treatment(肿瘤防治研究), 2002(1): 67-68. [46] WANG CJ, CHEN QQ, DENG L, et al.Hepatic artery infusion of cinobufotain for treating advance hepatocellu-lar carcinoma[J].Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases(中西医结合肝病杂志), 2001(1): 5-7. [47] WU HM, ZHU DZ, LING CQ, et al.Clinical observation on hepatic arterial intubation chemoembolization with cinobufacin for hepatocellular carcinoma[J]. Liaoning Journal of Traditional Chinese Medicine(辽宁中医杂志), 2000(3): 81-82. [48] DENG L, CHEN QQ, LU QH.Clinical observation of cinobufacin combined with interventional therapy for primary liver cancer[J].Journal of Interventional Radiology(介入放射学杂志), 1999(1): 43. [49] TIAN SY, XU AB, HUANG HH, et al.Observation of curative effect of cinobufacini combined with FOLFOX4 regimen in the treatment of 60 cases of advanced liver cancer[J]. Journal of China Prescription Drug(中国处方药), 2016, 14(11): 72-73. [50] ZHAO ZG, TANG ZQ.The clinical value of cinobufacini injection care for liver cancer[J]. Inner Mongolia Medical Journal(内蒙古医学杂志), 2015, 47(2): 172-175 [51] WANG SJ, XIE GQ.Clinical efficacy observation and nursing of Cinobufacini Injection on advanced primary liver cancer in 60 cases[J]. Journal of Modern Medicine & Health(现代医药卫生), 2011, 27(18): 2768-2770. [52] ZHANG XY, HU YH, TANG CG, et al.Clinical research of stereotactic conformal body y-knife and cinobufacini on patients with hepatocellular carcinoma[J]. Chinese Journal of Clinicians(Electronic Edition)[中华临床医师杂志(电子版)], 2011, 5(7): 1901-1905. [53] ZHOU XB.Clinical Observation of cinobufacini injection used to treat primary liver cancer in 58 cases[J]. China Practical Medicine(中国实用医药), 2010, 5(23): 6-7. [54] MA YJ, MA YP.Cinobufacini injection treatment of advanced primary liver cancer clinical observation[J]. Journal of Liaoning University of Traditional Chinese Medicine(辽宁中医药大学学报), 2010, 12(1): 124-125. [55] HUANG ZF, LI HZ, CHEN QS.Effects of Cinobufasu injection combined with western medicine on the quality of life and immune function in the treatment of advanced primary liver cancer[J].Journal of Yunnan University of Traditional Chinese Medicine(云南中医学院学报), 2009, 32(4): 47-49. [56] LIN Q, CHEN RF, LI ZH.Value of delisheng combined with hepatic artery chemoembolization and portal vein chemotherapy in hepatocellular carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition)[中华普通外科学文献(电子版)], 2008(5): 377-379. [57] ZHAO XD, LIU GM, LV YQ.Clinical observation of Delisheng injection combined with radiofrequency ablation in the treatment of advanced liver cancer[J]. Journal of Modern Oncology(现代肿瘤医学), 2006(8): 985-986. [58] SHU XH, TAN BX.Observation of short-term curative effect of cinobufulin combined with 5-fluorouracil in the treatment of advanced liver cancer[J]. Journal of Cancer Control and Treatment(四川肿瘤防治), 2004(2): 88-89. [59] CHEN Z, ZHAI XF, SU YH.Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer[J]. Journal of Integrative Medicine(中西医结合学报), 2003(3): 184-186. [60] LAI YQ, JIN Y, CHEN YY.Clinical analysis of cinobufacin combined with chemotherapy in the treatment of advanced hepatocellular carcin-oma[J]. Journal of Modern Oncology(陕西肿瘤医学), 2002(3): 217. [61] WU HM, ZHU DZ, LING CQ.Clinical observation on hepatic arterial intubation chemoembolization with cinobufacin for hepatocellular carcinoma[J]. Liaoning Journal of Traditional Chinese Medicine(辽宁中医杂志), 2000(3): 81-82. [62] CAI XY, ZHANG D.Clinical effect of hepatic artery injection of cinobufotalin combined with hyperthermic perfu-sion chemotherapy in the treatment of primary hepatocellular carcinoma[J]. Journal of Clinical Research(医学临床研究), 2019, 36(7): 3. [63] GUO YY, ZHAI XQ, LIU Q.et al.Clinical study of cinobufacini combined with TACE in the treatment of advanced liver cancer[J].Journal of Traditional Chinese Medicine University of Hunan(湖南中医药大学学报), 2016, 36(A01): 1. [64] LI XF.Clinical observation of cinobufacin injection combined with hepatic arterial chemoembolization in the treatment of primary liver cancer[J]. China Health Care & Nutrition(中国保健营养旬刊), 2014, 24(7): 32-33. [65] LIANG Y, LONG JZ, LIU H, et al.Study of cinobufotalin and interferon combined with transcatheter hepatic arterial chemoembolization on primary hepatocellular carcinoma[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine(现代中西医结合杂志), 2008(11): 1628-1630. [66] YANG YL, MA Y, CAO YJ, et al.Clinical observation of cinobufacini combined with interventional therapy (TACE) for hepatocellular carcinoma[J]. For All Health[大家健康(中旬版)], 2018, 12(1): 140-141. [67] DING JQ.Clinical efficacies of cinobufagin injection and tablet sequential for primary liver cancer: a report of 56 cases[J]. Journal of Clinical Research(医学临床研究), 2015, 32(3): 3. [68] LIU SH, LIU CL, DAI JH, et al.Protective effect of Delisheng injection on liver function and immune function of patients with primary liver cancer treated with stereotactic radiotherapy[J].Journal of Modern Oncology(现代肿瘤医学), 2006, 14(4): 3. [69] NI BQ, ZHANG ZH, CHEN RX, et al.Role of Cinobu facini injection combines with supportive care for advanced hepatoma[J].Internal Medicine(内科), 2009, 4(2): 197-199. [70] ZHU JF.Clinical observation of 58 cases of cinobufacini injection in the treatment of primary liver cancer[J]. Medical Information(医学信息), 2013(25): 542-543. [71] XU XH, WU Y, YI KJ, et al. Overview on systematic reviews of huachansu injection combined with transcatheter arterial chemoembolization for treatment of liver cancer[J/OL].Chinese Journal of Information on Traditional Chinese Medicine(中国中医药信息杂志).(2021-05-30)[2022-02-06].DOI:10.19879/j.cnki. 1005-5304.202105334. [72] REN SS, FAN S, GUO DY, et al. Systematic evaluation and meta-analysis of the efficacy and safety of cinobufagin injection combined with western medicine in the treatment of liver cancer[J/OL]. Journal of Hainan Medical University.(2021-01-31)[2022-02-06]. DOI: 10.13210/j.cnki.jhmu.20210713.001. [73] LIN L. RESEARCH ON.The risks of the local government financing platform based on entropy-weight andmatter-element model[J].Economic Theory and Business Management(经济理论与经济管理), 2012, (5): 65-71. [74] LI XF, XU JP.A comprehensive risk measurement model for enterprise technological innovation based on matter-element and extension set theory[J]. Chinese Journal of Management Science(中国管理科学), 2011, 19(3): 103-110. |
[1] | 方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24. |
[2] | 刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101. |
[3] | 夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970. |
[4] | 里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977. |
[5] | 逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981. |
[6] | 沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986. |
[7] | 刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006. |
[8] | 张雨琪, 徐昕怡, 朱兰, 朱彦. 药品剂型标准术语的比较研究[J]. 中国药物警戒, 2023, 20(8): 904-910. |
[9] | 王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934. |
[10] | 郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638. |
[11] | 梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594. |
[12] | 霍佩琼, 郑鹏, 苏振浩. 特殊或重大疾病零售药店开展药物警戒活动的思考[J]. 中国药物警戒, 2023, 20(4): 428-432. |
[13] | 叶培, 张鹤巍, 吕强, 叶小飞, 许金芳, 郭晓晶. 基于FAERS 数据库舒更葡糖逆转神经肌肉阻滞安全性研究[J]. 中国药物警戒, 2023, 20(3): 321-325. |
[14] | 刘亚迪, 王雪, 殷晓阳, 刘泽宇, 张晓朦, 张冰, 林志健. 基于CiteSpace和生物信息学技术评估葛根素在肿瘤辅助治疗中的临床应用与安全风险[J]. 中国药物警戒, 2023, 20(12): 1407-1414. |
[15] | 逄瑜, 刘博, 吴文宇, 田月洁, 王涛. 英国患者报告制度建立的浅析与启示[J]. 中国药物警戒, 2023, 20(11): 1259-1263. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||